Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with cTACE for Advanced HCC
NCT04652492Phase 2Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Zhongda Hospital, Southeast University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04652492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652492.